|
|
||||||||
B-
crystallin abrogates ischemic protection in cardiomyocytes
1 Department of Physiology, Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois 60153; and 2 Department of Medicine, University of California, San Diego, La Jolla, California 92093-0618
| |
ABSTRACT |
|---|
|
|
|---|
High levels of
B-crystallin are present in the cardiomyocyte, yet little is
understood about the function and importance of this protein. Like many
other small heat shock proteins,
B-crystallin forms large oligomeric
complexes whose size can be regulated by posttranslational
modifications. The size of these complexes can modify the function of
the protein. A naturally occurring COOH-terminal mutant has many
detrimental effects in the lens of the eye and altered oligomerization.
Therefore, we mutated the two COOH-terminal lysines of
B-crystallin
to glycines (K174/175G) and adenovirally mounted them to transduce
cardiomyocytes. We analyzed the effect of this mutation on
oligomerization, microtubular stabilization, and ischemic
outcome. A nearly 45% downward shift in complex size was
observed with the mutant by native PAGE followed by immunoblotting. The
overexpressed protein no longer protected the tubulin cytoskeleton against ischemic stress by confocal analysis. The mutant caused a 30% increase in cytosolic enzyme release with ischemia
compared with control, whereas a 33% decrease was associated with
wild-type
B-crystallin overexpression. We conclude that the COOH
terminus of
B-crystallin is crucial to its proper function.
heat shock protein; recombinant adenovirus; confocal microscopy
| |
INTRODUCTION |
|---|
|
|
|---|
MAMMALIAN
B-crystallin is a member of the family of small heat shock proteins
(smHSPs), which includes the lens
-crystallins and HSP25.
B-crystallin is an HSP by homology criteria and the classic
induction pattern with thermal stress (20). An important protective function of the smHSPs including
B-crystallin has been
well documented. Aoyama and coworkers (1) showed that
B-crystallin overexpression increased thermoprotection in
fibroblasts.
B-crystallin has long been recognized as a major
component in the lens of the eye contributing to the ability of this
protective shield to remain transparent despite extensive oxidative
insults. More recently, it was discovered that
B-crystallin is
present at significant levels in nonlenticular tissues, especially the heart and skeletal muscles (8, 19). We previously
demonstrated (25) that the expression of exogenous
B-crystallin correlated with protection against ischemic
damage in cardiac myocytes. Additionally, it was demonstrated that
B-crystallin associates with actin and desmin, with the desmin
interaction increasing in affinity with a decrease in pH, as during
ischemia (3, 5). Also, we showed (6)
that ectopic
B-crystallin preserves the tubulin cytoskeletal structure against ischemia-induced disruption in
cardiomyocytes. Further evidence of the importance of
B-crystallin
for proper cytoskeletal arrangements was shown in the cosegregation of
an
B-crystallin missense mutation (R120G) with a desmin-related myopathy in a French family (35).
The smHSPs contain an evolutionarily conserved
-crystallin domain,
which is preceded by an NH2-terminal domain. The
NH2-terminal domain is highly variable in size and is
generally buried in the aggregate formed by multiple individual HSPs
constituting a large oligomeric structure. The COOH-terminal region is
located toward the outside of the structure containing oligomerized
smHSPs (22). The COOH-terminal region of smHSP appears
relatively unstructured and is known to undergo numerous modifications.
These include the relatively unexplored addition of O-linked
N-acetylglucosamine to the COOH-terminal threonine (T170),
preliminarily thought to regulate the protective function and/or
subcellular localization of
B-crystallin (4, 30). Also,
a naturally occurring truncation of the four COOH-terminal amino acids
of
B-crystallin in the lens of the eye (which includes lysines
174/175), the degree of which increases with age, correlates with a
decay in the protective shield and an increase in cataract formation
(18). Furthermore, Takemoto and coworkers
(33) demonstrated by immobilizing the normally flexible
COOH-terminal region that this flexibility is necessary for chaperone
function. Using yeast two-hybrid screening with different sections of
the crystallins, Fu and Liang (11) found that the
COOH-terminal portion of
B-crystallin interacted and oligomerized
far better than the NH2-terminal portion. Other posttranslational modifications, in particular phosphorylation, do play
an important role in modifying smHSP and
B-crystallin function.
B-crystallin is phosphorylated via the mitogen-activated protein
(MAP) kinase pathway at serines 19, 45, and 59, which has been
demonstrated to decrease the oligomer size (10,
15).
Both of the smHSPs
B-crystallin and HSP25 form large oligomeric
complexes that are thought to be intrinsic to protection against
noxious stresses, possibly providing a "safe haven" for cellular
components. A number of studies have examined the link between
oligomeric size and chaperone function for the small HSPs and the role
that different domains of smHSPs play in oligomerization and chaperone
function (for reviews, see Refs. 24 and 28).
Several studies have explored the relative importance of various
regions of
B-crystallin by in vitro or prokaryotic assays. In one
such study, the mutagenesis of the COOH-terminal lysines was associated
with a decrease in thermoprotection in a prokaryotic thermokill assay
but no change in oligomerization (29). The authors suggest
that this electropositive region (K174/175) may be involved in the
interaction with unfolded proteins. Thus altering this domain would
decrease the chaperone activity of
B-crystallin but not necessarily
the oligomerization. However, the authors tested only bacterially
expressed recombinant proteins for oligomeric changes (and found no
difference). The significance of this basically charged region in an in
vivo mammalian cell model is unknown, especially with regard to a
physiological stress like ischemia. Therefore, we sought to
examine the importance of the COOH-terminal region of
B-crystallin
by mutating the two terminal COOH-terminal lysines (174/175) to neutral
glycines. The COOH-terminal mutant was adenovirally expressed in
cardiomyocytes, and subsequently we compared it with the similarly
expressed native protein on ischemic outcome, oligomeric
formation, and cytoskeletal stabilization.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Isolation of neonatal ventricular cardiomyocytes. Neonatal cardiomyocytes were isolated via collagenase/pancreatin digestion and Percoll gradient separation from 1- to 2-day old rats as previously described (23). They were plated at a density of ~500 cells/mm2 in 6-cm dishes precoated with gelatin in plating media (DMEM-M199, 4:1 vol/vol, with 10% horse serum and 5% fetal bovine serum supplemented with penicillin and streptomycin) for 18 h before adenovirus infection. For confocal studies, cells were plated at a density of 200 cells/mm2 on fibronectin-coated four-well chamber slides (Labtek; Fisher Scientific, Pittsburgh, PA).
Construction of adenoviral vectors.
The rat
B-crystallin adenovirus construction was previously
described (23). We used the shuttle vector
pACCMVpLpASR-(provided by Dr. Robert D. Gerard, University of Texas
Southwestern, Dallas, TX), which contains the 5' end of the adenovirus
serotype 5 genome (map units 0-17) in which the E1 region has been
replaced with the human cytomegalovirus (CMV) enhancer-promoter
followed by the pUC19 multiple cloning site and the SV40
polyadenylation region. For a control virus we used a
previously constructed non-transgene-containing adenovirus named SR
(23). For the COOH-terminal mutant, the sense strand
primer ACT GCA GCC CCT GGG GGG TAG ATT CCC TTT and the complementary
antisense strand were synthesized as well as primers to the flanking
regions of the pACCMVpLpASR
plasmid for PCR-based mutagenesis. The
resultant mutated cDNAs were sequenced to confirm the mutation before
construction of the recombinant adenovirus. Adenoviruses were generated
via standard cotransfection protocols with the mutant
B-crystallin-SR plasmid and pJM17, a plasmid containing the entire
adenovirus genome, into 293 cells (26). Virus was plaque
purified, amplified, CsCl gradient purified, and dialyzed before
spectrophotometric titering (OD260 × dilution × 1010 = particles/ml). Cells were infected with 100 particles/cell for 2 h in maintenance medium (DMEM-M199, 4:1
vol/vol) with 2% FCS. The medium was then changed to no-serum
maintenance medium. Experiments began ~40 h later.
Simulated ischemia and enzyme quantitation. Initial simulated ischemia experiments were performed by placing the cells in a hypotonic balanced salt solution (in mM: 1.3 CaCl2, 5 KCl, 0.3 KH2PO4, 0.5 MgCl2, 0.4 MgSO2, 69 NaCl, 4 NaHCO2, and 0.3 Na2HPO4) without glucose or serum. The plates were then placed in an airtight jar containing the oxygen-consuming GasPak system (BBL Microbiology Systems, Franklin Lakes, NJ) and flushed for 5 min with argon to rapidly achieve <0.2% O2. After 14 h, the dishes were removed from the chamber with the medium, and the cells were each assayed separately for enzyme content. Subsequent experiments, using normotonic ischemic buffer, produced identical ischemic protection results. After the medium was removed, the cells were scraped into 1 ml of cold PBS and sonicated (ultrasonic homogenizer 4710, Cole-Parmer, Vernon Hills, IL) for 15 s followed by 10 min of centrifugation at 150 g. The creatine phosphokinase (CK) in the medium and from the sonicated cells was quantified with a CK determination kit (Sigma, St. Louis, MO). From these values the percentage of CK released was calculated, and then these values were normalized to the enzyme released by control cells that were also made ischemic. This allowed us to pool data from several experiments that might have variable total CK release, because of cell plating variability and differences in the severity of the ischemic stress.
A whole cell toxicology assay kit (Sigma) was used to permit the measurement of cell viability as a function of mitochondria activity. This method is based on 2,3-bis [2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) cleavage. Functional mitochondrial dehydrogenase in the viable cells cleaves the tetrazolium ring of XTT, which produces orange formazan crystals that are measurable spectrophotometrically. Fifty thousand cells were plated in each well of a 96-well plate, infected, and stressed in the same manner as described above except that after ischemia the buffer was changed to 80 µl of isotonic balanced salt buffer containing 10 mM glucose and 20 µl of the XTT solution was added. The plates were placed back in the incubator and read at 450 nm 4 h later with a water-containing well for a blank. These data were analyzed in the same manner as the CK values.Protein analysis.
For denaturing PAGE, cells were harvested in solution B (in
mM: 20 NaCl, 20 Tris pH 7.5, and 0.1 EDTA) containing 1% Triton X-100,
0.5% deoxycholate, and 5 µM 2-mercaptoethanol. The samples were
vortexed vigorously and placed on ice for 15 min before 15-min centrifugation at 12,000 g. The concentration of the
supernatant was determined by Bradford assay, and equal amounts were
loaded on either Bio-Rad minigels for Western analysis or larger (16 cm) Hoefer setups for labeled extracts and native PAGE. For the [35S]methionine-labeled extracts equal trichloroacetic
acid-precipitable counts were fractionated through a 12% SDS-PAGE,
which was fixed, enhanced, dried, and exposed to film for the
appropriate length of time at
70°C. The phosphospecific rabbit
polyclonal anti-
B-crystallin (serine 59) was generously provided by
K. Kato (Institute for Developmental Research, Aichi Human Service
Center, Aichi, Japan) (15) via P. Eaton (Rayne Institute,
St. Thomas' Hospital, London, UK) (10).
B-crystallin (SPA 223;
Stressgen, Victoria, BC, Canada) with a horseradish
peroxidase-conjugated secondary anti-rabbit IgG and an ECL detection
kit (Amersham, Piscataway, NJ). The calculation of the size of
the
B-crystallin complexes was based on the pooling of four
independent native gels. For the linear extrapolation, Coomassie
blue-stained apoferritin (450-kDa monomer, 900-kDa dimer, 1,350-kDa
trimer) and urease (272-kDa trimer, 545-kDa hexamer; Sigma) were used
as standards.
Microtubular integrity assay. In brief, after 14 h of normotonic simulated ischemia, cells were methanol fixed and then washed with PBS before 20-min blocking with 10% goat serum-3% BSA in PBS. After being washed with PBS the cells were incubated for 1 h in 1:1,000 diluted monoclonal anti-tubulin (T5168, Sigma) in PBS containing 3% BSA. After additional PBS washing the cells were incubated with FITC-conjugated goat anti-mouse antibody at 1:100 for 1 h. After final PBS washes the slides were aspirated dry and sealed with coverslips and Vectashield mounting medium (Vector Labs, Burlingame, CA). Confocal microscopy was performed with a Bio-Rad MRC 1024 confocal microscope. The 488-nm-wavelength line of the krypton-argon laser was used for excitation, and the emitted light was collected at 522 nm. Image acquisition software settings (laser intensity, iris size, gain) were strictly maintained for all images taken on the same day to allow quantitative, paired comparisons. The Laser Sharp software of the confocal microscope was used for image analysis. The width of the pixel intensity histogram was found to be a reliable and sensitive measure of microtubule integrity. Further details were published previously (6).
Statistics. One-way ANOVA with post hoc Bonferroni t-test was used to determine statistic significance of CK release (see Fig. 2) and XTT bioreduction (see Fig. 3). Microtubular stability (see Fig. 4) comparisons utilized repeated-measures ANOVA, the equivalent of paired comparisons for multiple groups. Paired statistics were used because crucial parameters such as myocyte plating or the severity of ischemia were matched for all cells analyzed on any one day but were subject to day-to-day variation.
| |
RESULTS |
|---|
|
|
|---|
Because of the increased interest in the role of
B-crystallin
in the cardiovascular setting and particularly the importance of its
COOH terminus in protective function, we mutated the two terminal
lysines to glycines and then mounted the mutant and wild type in
adenovirus for use in cardiomyocytes. Figure
1A compares the expression and
size of denatured mutated and wild-type
B-crystallin by Western blot
analysis of a minigel-PAGE. In Fig. 1B, we used [35S]methionine-labeled cell extracts to show the slight
decrease in the size of the denatured
B-crystallin associated with
the mutation of these two lysines to glycines on a larger-resolving PAGE. Figure 1C depicts the size of the native
B-crystallin complexes as examined by 5% nondenaturing PAGE and
Western immunoblot. There is a dramatic downward shift with the
COOH-terminal mutant from 1,100 ± 138 to 610 ± 125 kDa
(n = 5). The broad nature of the bands may be due to
the heterologous nature of the complexes.
|
After having shown equivalent overexpression and a dramatic decrease in
the size of the native complex with the lysine mutant, we next examined
it in our simulated ischemia model. Figure
2 confirms the 33% decrease in CK
release we saw previously (25) with overexpression of
B-crystallin. However, the expression of the COOH-terminal
mutant produced a 30% increase in ischemic damage compared
with control and a 63% increase compared with wild-type
B-crystallin-overexpressing cells. To further confirm these results,
we looked at another marker of cellular damage, the reduction of XTT,
an indicator of functional mitochondrial dehydrogenase. These results
are displayed in Fig. 3 and again show a
complete loss of any ischemic protection with the lysine to
glycine mutant.
|
|
We next immunoprecipitated extracts from control,
B-crystallin-, and
mutated
B-crystallin-expressing cardiomyocytes with antibody to
B-crystallin to examine any differences in association with the
intermediate filament proteins desmin, tubulin, and vimentin. There is
evidence that the interaction of
B-crystallin with these proteins
may be altered under ischemic conditions in perfused hearts
(3). We could not detect any difference with the mutant via immunoprecipitation and subsequent Western blot analysis even with
extracts from ischemic cells (data not shown). This may be due
to the particular models, isolated cells vs. whole heart, or a
limitation of the immunoprecipitation methods used, or perhaps this
mutation does not affect this interaction.
Therefore, we next used a highly sensitive assay we recently developed
(6), a quantitative method for analyzing cytoskeletal integrity based on immunostaining and confocal microscopy. This method
examines the integrity of the entire cytoskeletal array. In our
previous study (6) we found the ischemia-induced
microtubular disruption to be similar to that caused by colchicine
treatment as assessed by this method of quantifying immunostaining by
measuring the pixel intensity scatter. A series of experiments was
performed comparing the microtubular integrity of control,
B-crystallin-, and COOH-terminal mutant-overexpressing
cardiomyocytes after ischemic stress. The results are
summarized in Fig. 4. This demonstrates that the additional stabilization of the microtubular array against ischemic stress with wild-type
B-crystallin overexpression
(vs. control) is lost with the lysine to glycine mutations.
|
Recently Ito et al. (15) demonstrated that phosphorylation
of
B-crystallin decreases its oligomerization and chaperone activity. Thus we examined our COOH-terminal mutant for
alteration in basal phosphorylation by Western blot with a
phosphospecific antibody to serine 59 of
B-crystallin. Figure
5 demonstrates that the mutant appears
phosphorylated, although in this particular experiment the ectopic
expression of both the wild type and the mutant is lower than in Fig.
1.
|
| |
DISCUSSION |
|---|
|
|
|---|
The major findings of this study are that 1) the
COOH-terminal lysines of
B-crystallin are required for protection
against ischemic damage in cardiomyocytes, 2) the
mutation of these two lysines produced a significant decrease in the
size of the native aggregate, and 3) this alteration also
diminishes its stabilization of the microtubular cytoskeleton.
Ischemic protection.
Previous work, primarily focused on the role of
B-crystallin in the
eye, indicated that the integrity of the COOH terminus was important
for its proper function. Bacterial thermokilling assays support the
importance of the COOH-terminal lysines by mutagenesis for proper
B-crystallin function (29). Similarly, protease
truncation experiments indicate this region is required to prevent
heat-induced denaturation (33). More recently, a random
mutagenesis approach followed by in vitro gal-lex binding experiments
showed diminished
B-crystallin function with mutations in the
COOH-terminal domain, suggesting that the charge of this region
stabilizes the complex (7). These approaches all use nonmammalian systems to examine a mammalian protein, which may affect
its native confirmation. The studies described in this present report
examine the same region, by altering its basic nature to a more neutral
one, in primary cardiac myocytes while determining its effect on
ischemic outcome, oligomerization, and cytoskeletal
stabilization. We determined that mutating the two COOH-terminal
lysines to glycines was detrimental to cardiomyocyte survival of
ischemic stress by cytosolic enzyme release (Fig. 2).
Interestingly, the 30% increase in CK release with the mutant
B-crystallin is very similar to the increased release with the antisense to another smHSP (HSP27) intervention in this same model (25). Our initial experiments (examining CK release) even
suggested a dominant-negative type function for the mutant (Fig. 2),
but the results from the other ischemic end points (Figs. 3 and
4) seem to indicate more a loss of the protective function associated with
B-crystallin overexpression than interference with endogenous
B-crystallin.
Oligomerization studies.
The oligomerization behavior of the smHSP also contributes in an
important way to its function. In the current study we suggest that the
charge of the COOH terminus may affect the size of the oligomer. Our
COOH-terminal mutant had a significant downward shift in oligomeric
size. It should also be noted that the native Western blots did not
show a signal for the endogenous
B-crystallin (~1,100 kDa)
whenever the mutant
B-crystallin (~610 kDa) was present. Whether
this is due to endogenous
B-crystallin oligomerizing with the mutant
B-crystallin in complexes with fewer subunits or a limitation of the
method used here we cannot say.
B-crystallin mutants. This may be due to the difference between utilizing
bacterially expressed recombinant protein studies and our in situ
cardiomyocyte approach. Also, we should point out that the murine
B-crystallin used by Plater and coworkers, somewhat uniquely, has an
alanine rather than a threonine at 170, so it would not be glycosylated in the same manner. Thus, if our mutant affected the glycosylation state and this affected function and/or oligomerization, this would
help explain the different outcome.
Phosphorylation and oligomerization.
Although our present study does not directly address the question of
the phosphorylation of
B-crystallin and its oligomerization, it does
deserve comment. Our COOH-terminal mutant, with decreased oligomerization, does not appear abnormally phosphorylated. Ito et al.
(15) demonstrated that constitutively phosphorylated
B-crystallin retained a reduced chaperone function and decreased aggregate size. In contrast, Eaton and coworkers (10)
found that increasing the phosphorylation of
B-crystallin with
phenylephrine did not alter the aggregate size.
B-crystallin phosphorylation with ischemia in the whole
heart and suggested that it may be protective of the contractile
apparatus. However, in a follow-up study this group did not find
dephosphorylation of
B-crystallin concomitant with its displacement
from ischemia-induced myofibrillar binding (12).
Also, in plants the chloroplast-localized smHSP HSP21, which
oligomerizes in vivo, does not appear to be phosphorylated at all
(29). Two additional studies specifically addressed
whether it is possible that this smHSP is an effector for
ischemic preconditioning in the heart. Armstrong et al.
(2) found an increase in
B-crystallin phosphorylation
and translocation with ischemia-reperfusion
injury in isolated cardiomyocytes that was not augmented with
ischemic preconditioning. However, Eaton and coworkers
(9) did find a correlation between the degree of
B-crystallin phosphorylation and translocation with ischemic preconditioning in perfused rat hearts. These models are all different from each other and from our own model, but they suggest that although
the phosphorylation of
B-crystallin is an important posttranslational modification, other factors may also determine aggregate size.
Truncation and oligomerization.
A recent study of
B-crystallin from human cataracts found a
disproportionately high amount of a truncated form, specifically missing the COOH-terminal lysine, which also had an altered
oligomerization state yet was still effective in preventing the
aggregation of purified lactalbumin (17). This naturally
occurring truncation has properties similar to our lysine-to-glycine
mutant except for its retained protective effect in an in vitro assay.
How can we reconcile increased cataract formation with lysine
truncation that is still able to prevent the malfolding of lactalbumin?
Koretz et al. (21) suggested that one can separate the
chaperone-like activities of
-crystallin (i.e., aggregation studies)
from its actual in vivo function. They showed that the chaperone
function is much reduced under more physiological conditions (i.e., in the presence of unchelated divalent cations) so it may not be as
relevant within the cell. This is incentive enough to examine results
from reconstitution assays via more applicable models.
Stabilization of cytoskeleton.
It has become apparent there are several smHSPs present at high levels
in the cardiovasculature, with
B-crystallin having specific
cytoskeletal associations (2, 3, 5, 6, 12, 13, 15, 23). It
has been proposed via immunolocalization experiments that
B-crystallin relocates with ischemia to the Z lines of the
myocardium, where it could serve as a stabilizer (13, 23).
In isolated cardiomyocytes subjected to heat stress,
B-crystallin
relocates to sarcomeric structures (34). There are also
data suggesting that
B-crystallin interacts in a specific manner
with various intermediate filaments in the cardiovasculature (3,
5) and in other cell types (37). The protection of the ischemia-induced disruption of the microtubular
cytoskeleton associated with ectopic expression of
B-crystallin is
abrogated when the expressed
B-crystallin has its two COOH-terminal
lysines mutated (Fig. 4). This also supports a scheme with
B-crystallin, particularly in the cardiovascular setting, playing a
significant role in cytoskeletal stability, especially in responses to stress.
B-crystallin is in the part of the complex that interacts with malfolded cellular proteins (32, 33). It is possible that the lysine to glycine mutation leads to the loss of protection against
ischemic injury via decreased ability to interact with partially malfolded proteins and thus potentially attenuate the denaturing process.
In conclusion, our studies indicate that the protective effect of
B-crystallin expression against ischemic stress, as assessed by two separate end points, is abrogated by mutating the two
COOH-terminal lysines of crystallin. This same mutation caused a
dramatic decrease in the oligomerization status of
B-crystallin. A
consequence of this mutation was the loss of the preservation of the
microtubular cytoskeleton against ischemia-induced disruption
associated with ectopically expressed
B-crystallin. In summary, we
believe the COOH terminus region of
B-crystallin is important for
its proper function.
| |
ACKNOWLEDGEMENTS |
|---|
These studies were supported by the Ralph and Marian Falk Trust for Medical Research (J. L. Martin), National Heart, Lung, and Blood Institute (NHLBI) Grant F32-HL-10042 (W. F. Bluhm), American Heart Association Grant GIA 0050276N (R. Mestril), and NHLBI Grant R37-HL-49434 (W. H. Dillman).
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: J. L. Martin, Cardiovascular Institute, Dept. of Medicine, Loyola Univ. Medical Center, 2160 S. First Ave., Maywood, IL 60153 (E-mail: jmart10{at}lumc.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published March 14, 2002;10.1152/ajpheart.00512.2001
Received 11 June 2001; accepted in final form 11 March 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Aoyama, A,
Frohli E,
Schafer R,
and
Klemenz R.
B crystallin expression in mouse NIH 3T3 fibroblasts: glucocorticoid responsiveness and involvement in thermal protection.
Mol Cell Biol
13:
1824-1835,
1993
2.
Armstrong, SC,
Shivell CL,
and
Ganote CE.
Differential translocation or phosphorylation of
B-crystallin cannot be detected in ischemically preconditioned rabbit cardiomyocytes.
J Mol Cell Cardiol
32:
1301-1314,
2000[ISI][Medline].
3.
Barbato, R,
Menabo R,
Dainese P,
Carafoli E,
Schiaffino S,
and
Di Lisa F.
Binding of cytosolic proteins to myofibrils in ischemic rat hearts.
Circ Res
78:
821-828,
1996
4.
Benjamin, IJ,
Kang J,
Xiao X,
and
Bellotto D.
Dynamic changes in O-GlcNAcylation and phosphorylation of cardiac
B-crystallin after heat stress and ischemia (Abstract).
Circulation
100, suppl:
290,
1999.
5.
Bennardini, F,
Wrzosek A,
and
Chiesi M.
B-crystallin in cardiac tissue: association with actin and desmin filaments.
Circ Res
71:
288-294,
1992
6.
Bluhm, W,
Martin JL,
Mestril R,
and
Dillmann WH.
Specific heat shock proteins protect microtubules during simulated ischemia in cardiac myocytes.
Am J Physiol Heart Circ Physiol
275:
H2243-H2249,
1998
7.
Boelens, WC,
Croes Y,
de Ruwe M,
de Reu L,
and
de Jong WW.
Negative charges in the C-terminal domain stabilize the
B-crystallin complex.
J Biol Chem
273:
28085-28090,
1998
8.
Dubin, RA,
Wawrousek EF,
and
Piatigorsky J.
Expression of the murine
B-crystallin is not restricted to the lens.
Mol Cell Biol
9:
1083-1091,
1989
9.
Eaton, P,
Awad WI,
Miller JI,
Hearse DJ,
and
Shattock MJ.
Ischemia preconditioning: a potential role for constitutive low molecular weight stress protein translocation and phosphorylation?
J Mol Cell Cardiol
32:
961-971,
2000[ISI][Medline].
10.
Eaton, P,
Fuller W,
Bell JR,
and
Shattock MJ.
B-crystallin translocation and phosphorylation: signal transduction pathways and preconditioning in the isolated rat heart.
J Mol Cell Cardiol
33:
1659-1671,
2001[ISI][Medline].
11.
Fu, L,
and
Liang JJN
Detection of protein-protein interactions among lens crystallins in a mammalian two-hybrid system assay.
J Biol Chem
277:
4255-4260,
2002
12.
Golenhofen, N,
Htun P,
Ness W,
Koob R,
Schaper W,
and
Drenkhahn D.
Binding of the stress protein
B-crystallin to cardiac myofibrils correlates with the degree of myocardial damage during ischemia/reperfusion in vivo.
J Mol Cell Cardiol
31:
569-580,
1999[ISI][Medline].
13.
Golenhofen, N,
Ness W,
Koob R,
Htun P,
Schaper W,
and
Drenkhahn D.
Ischemia-induced phosphorylation and translocation of stress protein
B-crystallin to Z lines of myocardium.
Am J Physiol Heart Circ Physiol
274:
H1457-H1464,
1998
14.
He, H,
Meyer M,
Martin JL,
Lou X,
Lew WYW,
Hilal-Dandan R,
and
Dillmann WH.
The effects of mutant and antisense RNA of phospholamban on SR Ca-ATPase activity and cardiac myocyte contractility.
Circulation
100:
974-980,
1999
15.
Ito, H,
Kamei K,
Iwamoto I,
Inaguma Y,
Nohara D,
and
Kato K.
Phosphorylation-induced change of the oligomerization of
B-crystallin.
J Biol Chem
276:
29934-29941,
2001.
16.
Jakob, U,
Gaestel M,
Engel K,
and
Buchner J.
Small heat shock proteins are molecular chaperones.
J Biol Chem
268:
1517-1520,
1993
17.
Jimenez-Asensio, J,
Colvis CM,
Kowalak JA,
Duglas-Tabor Y,
Datiles MB,
Moroni M,
Mura U,
Rao CM,
Balasubramanian D,
Janjani A,
and
Garland D.
An atypical form of
B-crystallin is present in high concentration in some human cataractous lenses. Identification and characterization of aberrant N- and C-terminal processing.
J Biol Chem
274:
32287-32294,
1999
18.
Kamei, A,
Hamaguchi T,
Matsuura N,
Iwase H,
and
Masuda K.
Post-translational modification of
B-crystallin of normal human lens.
Biol Pharm Bull
23:
226-230,
2000[ISI][Medline].
19.
Kato, K,
Shinohara H,
Kurobe N,
Inaguama Y,
Shimizu K,
and
Ohshima K.
Tissue distribution and developmental profiles of immunoreactive
B-crystallin in the rat determined with a sensitive immunoassay system.
Biochim Biophys Acta
1074:
201-208,
1991[Medline].
20.
Klemenz, R,
Frohli E,
Steiger RH,
Schafer R,
and
Aoyama A.
B-crystallin is a small heat shock protein.
Proc Natl Acad Sci USA
88:
3652-3656,
1991
21.
Koretz, JF,
Doss EW,
and
Reid GH.
Analysis of the factors involved in the loss and restoration of the chaperone-like function of
-crystallin.
Biochem Biophys Res Commun
231:
270-276,
1997[ISI][Medline].
22.
Leroux, MR,
Melki R,
Gordon B,
Batelier G,
and
Candido EPM
Structure-function studies on small heat shock protein oligomeric assembly and interaction with unfolded polypeptides.
J Biol Chem
272:
24646-24656,
1997
23.
Lutsch, G,
Vetter R,
Offhaus U,
Grone HJ,
Klemenz R,
Schimke I,
Stahl J,
and
Benndorf R.
Abundance and location of the small heat shock proteins HSP25 and
B-crystallin in rat and human heart.
Circulation
96:
3466-3476,
1997
24.
MacRae, TH.
Structure and function of small heat shock protein/
-crystallin proteins: established concepts and emerging ideas.
Cell Mol Life Sci
57:
899-913,
2000[ISI][Medline].
25.
Martin, JL,
Mestril R,
Hilal-Dandan R,
Brunton LL,
and
Dillmann WH.
Small heat shock proteins and protection against ischemic injury in cardiac myocytes.
Circulation
96:
4343-4348,
1997
26.
McGrory, WJ,
Bautista DS,
and
Graham FL.
A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5.
Virology
163:
614-617,
1988[ISI][Medline].
27.
Mehlen, P,
Preville X,
Chareyron P,
Briolay J,
Klemenz R,
and
Arrigo AP.
Constitutive expression of human hsp27, Drosophila hsp27, or human
B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts.
J Immunol
154:
363-374,
1995[Abstract].
28.
Mestril, R,
and
Dillmann WH.
Heat shock proteins and protection against myocardial ischemia.
J Mol Cell Cardiol
27:
45-52,
1995[ISI][Medline].
29.
Plater, ML,
Goode D,
and
Crabbe MJC
Effects of site-directed mutations on the chaperone-like activity of
B-crystallin.
J Biol Chem
271:
28558-28566,
1996
30.
Roquemore, EP,
Chevrier MR,
Cotter RJ,
and
Hart GW.
Dynamic O-GlcNAcylation of the small heat shock protein
B-crystallin.
Biochemistry
35:
3578-86,
1996[Medline].
31.
Suzuki, TC,
Krawitz DC,
and
Vierling E.
The chloroplast small heat-shock protein oligomer is not phosphorylated and does not dissociate during heat stress in vivo.
Plant Physiol
116:
1151-1161,
1998
32.
Takemoto, L,
and
Boyle D.
Molecular chaperone properties of the high molecular weight aggregate from aged lens.
Curr Eye Res
13:
35-44,
1994[ISI][Medline].
33.
Takemoto, L,
Emmons T,
and
Horwitz J.
The C-terminal region of
-crystallin: involvement in protection against heat-induced denaturation.
Biochem J
294:
435-438,
1993.
34.
Van de Klundert, FAJM,
Gijsen MLJ,
van den IJssel PRLA,
Snoeckx LHEH,
and
de Jong WW.
B-crystallin and hsp25 in neonatal cardiac cells-differences in cellular localization under stress conditions.
Eur J Cell Biol
75:
38-45,
1998[ISI][Medline].
35.
Vicart, P,
Caron A,
Guicheny P,
Li Z,
Prevost MC,
Faure A,
Chateau D,
Chapon F,
Tome F,
Dupret JM,
Paulin D,
and
Fardeau M.
A missense mutation in the
B-crystallin chaperone gene causes a desmin-related myopathy.
Nat Genet
20:
92-95,
1998[ISI][Medline].
37.
Wisniewski, T,
and
Goldman J.
B-crystallin is associated with intermediate filaments in astrocytoma cells.
Neurochem Res
23:
385-392,
1998[ISI][Medline].
This article has been cited by other articles:
![]() |
X. Wang, R. Klevitsky, W. Huang, J. Glasford, F. Li, and J. Robbins {alpha}B-Crystallin Modulates Protein Aggregation of Abnormal Desmin Circ. Res., November 14, 2003; 93(10): 998 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Webster Serine Phosphorylation and Suppression of Apoptosis by the Small Heat Shock Protein {alpha}B-Crystallin Circ. Res., February 7, 2003; 92(2): 130 - 132. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |